in Newswire May 3, 2019

Class Action: Combivent Respimat Asthma Inhaler Contains Far Fewer Doses Than Advertised [UPDATE]

by Corrado Rizzi

Last Updated on October 7, 2020

Ignacuinos v. Boehringer Ingelheim Pharmaceuticals, Inc.

Filed: May 3, 2019 § 3:19-cv-00672

A COPD sufferer alleges Boehringer Ingelheim's Combivent Respimat asthma inhaler contains far fewer than the 120 doses promised in the advertising and marketing of the treatment.




Case Updates

October 8, 2020 – Lawsuit Dismissed

This browser does not support PDFs. Please download the PDF to view it: Download PDF.

Last Updated on October 7, 2020 — 2:10 PM

Corrado Rizzi

Corrado Rizzi is the Managing Editor and a writer for

About is a group of online professionals (designers, developers and writers) with years of experience in the legal industry.

Learn More

Before commenting, please review our comment policy.